A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）

NCT06908876 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

150

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Macular Oedema

Interventions

BIOLOGICAL: IBI302
BIOLOGICAL: IBI302
DRUG: Faricimab

Sponsor

Innovent Biologics Technology Limited (Shanghai R&D Center)